Biogen Idec to limit R&D and SG&A costs
This article was originally published in Scrip
Executive Summary
Biogen Idecwill squeeze the impact of R&D and SG&A spending on its revenues in order to sustain and drive growth. The firm said that this will reduce its two main expenses as a percentage of total revenues.